Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. - Michels,S.; Rosenfeld,P.J.; Puliafito,C.A. (Ophthalmology, 2005)